Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Zynerba Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Zynerba Pharmaceuticals is a U.S. public bio/pharmaceutical company that focuses on developing transdermal cannabinoid treatments for patients with high unmet medical needs. It has raised $50.4 million in a secondary public offering, as reported in the PharmSource Lead Sheet on January 26, 2017.

Corporate Highlights

  • Zynerba Pharmaceuticals was incorporated in Delaware in January 2007
  • Corporate Headquarters: Devon, PA – approximately 3,800 square feet of office space
  • As of March 10, 2016, they had 10 employees
  • Stock Exchange: NASDAQ
  • Stock Symbol: ZYNE

Sourcing Opportunities

  • Zynerba Pharmaceuticals plans to use the proceeds to fund clinical trials with ZYN001 and ZYN002, including:
    • ZYN002 – To complete a Phase II study:
      • For treatment of Fragile X Syndrome
      • Dosage Form: Semi-solid – Non-sterile
      • Nature of API: Chemical – Controlled substance
      • Therapeutic Area: Muscular/Musculoskeletal; Neurology/CNS; Pediatric
  • ZYN001 – To initiate a Phase I study:
    • For treatment of fibromyalgia and peripheral neuropathic pain
    • Dosage Form: Patch
    • Nature of API: Chemical – Controlled substance
    • Therapeutic Area: Analgesic – Non-narcotic; Neurology/CNS; Oncology – Other
  • The company contracts with contract research organizations (CROs) to conduct ongoing and planned clinical trials.
  • Zynerba Pharmaceuticals does not own or operate manufacturing facilities. They currently rely on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • Zynerba Pharmaceuticals has no sales, marketing or distribution infrastructure and experience.
  • Drug Product Pipeline

    Product Candidate Indication Dosage Form Status Next Anticipated Step
    ZYN001 Fibromyalgia Patch Preclinical Phase I trial expected to begin in H1 2017
    ZYN001 Peripheral Neuropathic Pain Patch Preclinical Phase I trial expected to begin in H1 2017
    ZYN002 Fragile X Syndrome Semi-solid – Non-sterile Phase II TBA
    ZYN002 Osteoarthritis in Knees Semi-solid – Non-sterile Phase II Results expected in H1 2017
    ZYN002 Refractory Epilepsy in Adults Semi-solid – Non-sterile Phase II Results expected in H1 2017

    Finances

    (In $ thousands) 2015 2014
    Revenues
    278,900
    810,012
    R&D Expenditures
    7,445,669
    2,401,406
    General & Administrative Expenditures
    5,364,390
    4,076,339
    Total Operating Expenses
    12,810,059
    5,667,733

    Contact Information

    Zynerba Pharmaceuticals, Inc. Key Officers
    80 W. Lancaster Avenue, Suite 300 Armando Anido, CEO
    Devon, PA 19333 USA Brian Boyd, VP, Manufacturing
    Phone: +1-484-581-7505 Donna L. Gutterman, VP, Medical Affairs
    Web: www.zynerba.com Nancy Tich, PhD, VP, Clinical

    Related posts:
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Clearside Biomedical, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Synthetic Biologics, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Collegium Pharmaceutical, Inc.

    Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

    More posts by Scotty Chung-Siu